Is Rapamycin (Sirolimus) Safe While Trying to Conceive?

What Is Rapamycin (Sirolimus) and Why Are Women Using It?

Rapamycin, sold under the brand name Rapamune, is an mTOR (mechanistic target of rapamycin) inhibitor originally approved by the FDA in 1999 for prevention of kidney transplant rejection. Over the past several years it has gained significant off-label attention in longevity medicine circles, with some clinicians prescribing low-dose weekly regimens for healthy women in their 30s, 40s, and 50s who are interested in extending healthspan.

Women are reaching for it across several life stages and conditions:

• Transplant recipients of reproductive age who need ongoing immunosuppression
• Women with certain cancers (lymphangioleiomyomatosis, for example, is an FDA-approved sirolimus indication that affects women almost exclusively)
• Healthy women using it off-label for longevity, sometimes alongside GLP-1 agonists or hormone therapy
• Women with PCOS exploring mTOR inhibition for metabolic and androgen benefit

The appeal is real. The fertility risk is equally real.

How Rapamycin Works in the Body

Sirolimus binds FK-binding protein 12 (FKBP12), and that complex then inhibits mTOR complex 1 (mTORC1). mTOR signaling is not a background pathway. It regulates cell proliferation, differentiation, and survival throughout the body, including in the ovary, endometrium, and developing embryo. Blocking mTOR during a period when those processes are most active, specifically at fertilization and early implantation, carries direct biological consequences.

The Longevity-Use Explosion and Why TTC Women Are Caught in It

The off-label longevity use of rapamycin is increasing. A 2023 survey published in GeroScience estimated that roughly 1,500 to 2,000 Americans were using rapamycin off-label for aging, and that number has grown substantially since. Many of these users are women in perimenopause, but a meaningful subset are women in their late 30s who are simultaneously thinking about a last pregnancy. That overlap is clinically dangerous and underappreciated.

Rapamycin and Female Fertility: What the Data Actually Show

The effect of sirolimus on female reproductive function is not theoretical. Stop here and read this carefully if you are trying to conceive.

Ovarian Effects

MTOR signaling governs primordial follicle activation, oocyte maturation, and corpus luteum function. Suppressing it with sirolimus has measurable consequences for ovarian biology.

A 2012 study in Biology of Reproduction demonstrated that sirolimus significantly impairs follicular development in mouse models by blocking the PI3K-mTOR pathway in granulosa cells. More clinically relevant, a 2021 retrospective analysis of female kidney transplant recipients on sirolimus-based regimens found menstrual irregularity in approximately 30 percent of premenopausal women on sirolimus, compared with 12 percent of those on calcineurin inhibitor-based regimens.

This matters. Menstrual irregularity in this context often reflects anovulation, which directly impairs your ability to conceive.

Endometrial Receptivity

Endometrial preparation for implantation depends on precisely timed progesterone-driven mTOR signaling. Experimental data show that mTOR inhibition during the implantation window reduces endometrial stromal cell decidualization, a process that is non-negotiable for successful embryo implantation. This suggests sirolimus could impair implantation even if ovulation does occur.

Male Partner Consideration

If your male partner is using rapamycin for longevity, he should know that sirolimus impairs spermatogenesis in animal models and has been associated with oligospermia and azoospermia in case reports in male transplant recipients. Both partners may need to stop the drug before attempting conception.

Pregnancy Safety: The FDA Label and Human Data

Here is a framework for thinking about the rapamycin-in-pregnancy evidence base. Evidence in this area falls into three tiers: animal data (substantial and concerning), human transplant-registry data (limited and mixed), and prospective controlled human pregnancy studies (essentially nonexistent). Most of what clinicians say about sirolimus and pregnancy is extrapolated from tier one and tier two.

What the FDA Label States

The FDA prescribing information for Rapamune is unambiguous. Under the Pregnancy subsection, the label states that sirolimus can cause fetal harm when administered to a pregnant woman. It further specifies:

• Women of childbearing potential must use effective contraception before starting sirolimus, during treatment, and for 12 weeks after the last dose.
• The drug should be avoided during pregnancy unless the benefit clearly outweighs fetal risk, a threshold almost never met in the off-label longevity context.

Twelve weeks is not an arbitrary number. Sirolimus has a long half-life of approximately 62 hours in stable transplant patients, and tissue accumulation means drug activity persists well beyond the last dose.

Animal Embryotoxicity Data

In rats and rabbits, sirolimus produced embryo and fetal toxicity at doses approximately 0.2 to 0.5 times the clinical human dose based on body surface area. Effects included:

• Reduced fetal weight
• Delayed ossification (bone development)
• Increased post-implantation loss
• Omphalocele and other structural abnormalities at higher doses

These are not marginal findings. They occurred at exposures below what a typical transplant patient receives.

Human Data: Transplant Registry Evidence

The most systematic human data come from transplant registries. The National Transplantation Pregnancy Registry (NTPR) has collected outcomes data from pregnant transplant recipients for decades. A 2019 analysis from the NTPR, published in Transplantation, found that women who conceived on mTOR inhibitor-containing regimens had higher rates of preterm birth, low birthweight, and pregnancy loss compared with the general population, though the registry authors cautioned that transplant recipients have multiple confounding risk factors.

Critically, the NTPR and major transplant societies now recommend switching women from sirolimus to calcineurin inhibitor-based regimens before conception when pregnancy is planned. This is not a theoretical preference. It reflects accumulated clinical experience showing worse outcomes when sirolimus is continued through pregnancy.

The Off-Label Longevity Context

Here is the stark contrast: a transplant patient may face a genuine risk-benefit calculation where continuing immunosuppression is necessary for organ survival. A healthy woman taking low-dose rapamycin weekly for longevity has no comparable justification for continuing it through a pregnancy attempt. There is no benefit that could reasonably outweigh embryotoxic risk in that context. Stop the drug. Wait the 12 weeks. Then try to conceive.

Rapamycin and Breastfeeding

The short answer is: do not breastfeed while taking sirolimus.

The LactMed entry for sirolimus notes that sirolimus is present in breast milk based on limited case report data. One published case found sirolimus concentrations in breast milk reaching approximately 45 percent of the maternal serum level, a ratio high enough to expose a nursing infant to immunosuppressive concentrations of the drug.

An infant's immune system is actively maturing. Exposing it to an mTOR inhibitor during this window could theoretically impair immune development, though direct human infant outcome data are absent because no study would ethically enroll nursing infants in such research.

LactMed concludes that breastfeeding is not recommended during sirolimus treatment. The American Academy of Pediatrics has not formally rated sirolimus for breastfeeding compatibility, but the weight of pharmacokinetic concern supports avoiding it entirely.

If you are a transplant recipient who needs sirolimus and wants to breastfeed, speak with your transplant nephrologist and maternal-fetal medicine specialist about whether a temporary switch to a lactation-compatible immunosuppressant is feasible. Options do exist for some patients.

Who Should Stop Rapamycin Before Trying to Conceive?

The answer is: every woman using sirolimus for any indication who plans to attempt pregnancy.

Women Using Rapamycin Off-Label for Longevity

This group has the clearest answer and the least complicated path. There is no medical indication compelling you to continue. Stop the drug. Use effective contraception for 12 weeks from your last dose. Then attempt conception.

Do not let a longevity prescriber tell you the dose is "too low to matter." The FDA contraception requirement applies regardless of dose, and animal toxicity has been documented at sub-therapeutic exposures.

Transplant Recipients Planning Pregnancy

This group requires a coordinated care team. ACOG Practice Bulletin guidance on pregnancy in women with solid organ transplants recommends that transplant recipients be counseled about contraception and conception timing, ideally deferring pregnancy until at least one year post-transplant and when graft function is stable. If you are on sirolimus, work with your transplant team to transition to a tacrolimus-based or cyclosporine-based regimen at least three to six months before attempting conception, giving the sirolimus adequate washout time.

Women with LAM (Lymphangioleiomyomatosis)

LAM is an FDA-approved indication for sirolimus and affects women almost exclusively, typically in the reproductive years. The LAM Foundation and pulmonary guidelines note that sirolimus should be stopped before conception. Some women with LAM experience disease progression during pregnancy because estrogen drives LAM lesion growth independently of mTOR, so planning pregnancy with LAM requires subspecialty counseling from a pulmonologist experienced in the condition as well as a maternal-fetal medicine specialist.

Women with PCOS

Some integrative and longevity-oriented clinicians prescribe low-dose rapamycin off-label to women with PCOS for its potential metabolic and androgenic benefits, extrapolating from animal data showing mTOR inhibition can reduce androgen production. This remains entirely experimental in women with PCOS, with no clinical trial data supporting efficacy or safety for this indication. Women with PCOS are already at elevated risk for anovulatory infertility. Adding a drug that further suppresses follicular development is doubly counterproductive if conception is a goal.

What Happens If You Accidentally Conceive on Rapamycin?

This is a real scenario. Women on off-label longevity regimens may not be using contraception consistently, or may not have been counseled about the 12-week washout requirement.

If you discover you are pregnant while taking sirolimus, or within 12 weeks of your last dose, take these steps immediately:

1. Stop sirolimus. Do not take another dose.
2. Call your prescribing clinician the same day.
3. Refer immediately to a maternal-fetal medicine (MFM) specialist for early pregnancy risk counseling.
4. Consider early anatomic survey ultrasound (typically 18 to 20 weeks) and possibly earlier detailed first-trimester imaging to assess structural fetal development.
5. Register with the National Transplantation Pregnancy Registry if you are a transplant recipient, or ask your MFM if voluntary case reporting is appropriate.

The risk is not zero, but a single brief exposure before a missed period is a different situation from months of exposure through organogenesis. An MFM specialist can help you interpret what the timing of your exposure actually means for your specific pregnancy.

Do not make decisions based on generic internet information. Get specialist input.

The Evidence Gap in Women: What We Don't Know

Women have been historically excluded from drug trials, and sirolimus is not an exception. A 2020 analysis of FDA-approved drug trials found that women represented fewer than 40 percent of participants in key immunosuppressant trials, and pregnancy was universally an exclusion criterion.

This means virtually everything we say about sirolimus and conception, implantation, fetal development, and lactation is extrapolated from animal models or inferred from small case series in transplant recipients, who have multiple confounding health variables. There are no randomized controlled trial data in healthy women trying to conceive. There are no prospective cohort studies. There are no systematic lactation pharmacokinetic studies.

What this means for you practically: the existing data are bad enough to prohibit use, and the absence of reassuring data in humans is itself a warning signal, not a green light. The phrase "we don't know for sure" should not be read as permission to continue. It means the risk is unquantified, not absent.

Contraception Requirements While on Rapamycin

The FDA label specifies that women of childbearing potential must use highly effective contraception before starting, throughout treatment, and for 12 weeks after the last dose.

"Highly effective" in this context means methods with a failure rate of less than 1 percent per year with typical use. Practically, that means:

• Combined hormonal contraceptives (pill, patch, ring)
• Progestin-only implant or hormonal IUD
• Copper IUD
• Tubal ligation or vasectomy

Condoms alone do not meet this threshold. If you are using rapamycin for longevity and relying on condoms as your only contraception, you are not complying with the FDA label requirement.

One practical note for women on combined oral contraceptives: sirolimus is metabolized by CYP3A4 and P-glycoprotein, the same pathways involved in estrogen and progestin metabolism. Drug-drug interactions are possible, though clinically the combined pill is generally considered adequate contraception in sirolimus-treated patients when used consistently.

Safer Alternatives to Rapamycin for Women Trying to Conceive

If you were using rapamycin for a specific clinical goal, ask your clinician about alternatives that carry no known embryotoxic risk:

• Metabolic health / insulin sensitivity in PCOS: Metformin has a long safety record in early pregnancy and is sometimes continued through the first trimester in women with PCOS. ACOG and ASRM both recognize metformin as an option for ovulation induction in PCOS.
• Longevity / metabolic optimization: Lifestyle interventions including time-restricted eating, resistance training, and dietary protein optimization have overlapping mTOR-related biological effects with none of the reproductive risk. These are not equivalent to sirolimus pharmacologically, but they are the appropriate substitute during a conception attempt.
• Anti-aging motivation: Some clinicians are exploring NAD+ precursors, berberine, and metformin for longevity-adjacent goals in women planning pregnancy. The evidence base for all of these is thin, but their reproductive safety profiles are substantially better characterized than sirolimus.

Life-Stage Summary: Rapamycin Across the Reproductive Years

| Life Stage | Rapamycin Use | Recommendation | |---|---|---| | Reproductive years, TTC | Off-label or transplant | Stop immediately; 12-week washout before conception | | Pregnant | Any indication | Contraindicated; fetal harm documented in animals | | Postpartum / breastfeeding | Any indication | Not recommended; drug present in breast milk | | Perimenopause (longevity use) | Off-label | Contraception still required if any uterus present and not confirmed post-menopausal | | Post-menopause | Off-label or transplant | Reproductive safety concern resolved; other risks apply |

Women in perimenopause deserve a specific note: menopause is a clinical diagnosis, typically defined as 12 consecutive months of amenorrhea without another cause. Until you have met that threshold, conception remains possible, and the contraception requirement on the FDA label still applies to you.